TMCnet News
Research and Markets: Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals DominatingDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/v8dx35/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating" report to their offering. One of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis. Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologcs for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics. Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders. Key vendors dominating this space include
Other vendors mentioned in the report are
Key questions answered in this report:
For more information visit http://www.researchandmarkets.com/research/v8dx35/global
|